Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Biocurie Inc. holds a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This activity involves 1 distinct examiner, reflecting a very narrow prosecution footprint at the present time for the company's biotechnological innovations.
The prosecution is situated within a distinct art unit. BAILEY, STEVEN WILLIAM is the busiest examiner assigned to the company, currently responsible for the pending office action. This single action constitutes the entirety of the active examination workload for the portfolio.
The concentration of work under one examiner in a single art unit indicates that the company is navigating a specific regulatory or technical path. Practitioners should focus on examiner-specific preferences and past rulings to optimize the chances of a favorable outcome in this pharmaceutical matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAILEY, STEVEN WILLIAM | 1 | 31.6% | +15.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17959537 | DATA-DRIVEN PROCESS DEVELOPMENT AND MANUFACTURING OF BIOPHARMACEUTICALS | BAILEY, STEVEN WILLIAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17959537 | DATA-DRIVEN PROCESS DEVELOPMENT AND MANUFACTURING OF BIOPHARMACEUTICALS | BAILEY, STEVEN WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17959537 | DATA-DRIVEN PROCESS DEVELOPMENT AND MANUFACTURING OF BIOPHARMACEUTICALS | BAILEY, STEVEN WILLIAM | 1687 | §101§103 | Final Rejection | — | Pending | Oct 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBiocurie Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Steven William Bailey has the most, with 1 of Biocurie Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
